Background: Most guidelines recommend that patients who have undergone curative resection for primary colorectal cancer are followed up for 5 years with regular blood carcinoembryonic antigen (CEA) tests to trigger further investigation for recurrence. However, CEA may miss recurrences, or patients may have false alarms and undergo unnecessary investigation. 
Introduction
After initial treatment for colorectal cancer, most clinicians in Europe and North America follow up patients to detect asymptomatic recurrence. Guidelines 1 -5 recommend using more than one diagnostic modality, and most clinicians employ a combination of clinical examination, carcinoembryonic antigen (CEA) testing, some imaging (usually CT of the chest, abdomen and pelvis) and colonoscopy to detect intraluminal recurrence.
Two recent trials, FACS 6 and CEAwatch 7 , have confirmed that including CEA testing as part of follow-up advances diagnosis, more than doubling the number of recurrences that can be treated surgically with curative intent. However, both trials have suggested that the common approach to testing recommended by guidelines (acting on the results of single tests) is suboptimal. In the FACS trial, recurrences were missed in patients who had experienced a gradual rise in CEA level, and it was suggested previously that this might be avoided by considering the trend in a series of results over time 8 . In the CEAwatch trial, further investigation was based on CEA trend, on the basis of evidence from other studies 9 -14 that it provides better diagnostic yield than a single measurement.
Critics of intensive follow-up regimens point to the lack of evidence that diagnosis of recurrence before symptoms develop improves survival. It is therefore important that the chosen follow-up regimen does not cause harm and that it is cost-effective. A potential problem with acting on a single raised measurement is that it can cause false alarms (leading to unnecessary additional tests). This article reports an observational analysis of CEA data from the FACS trial to quantify the advantage of making clinical decisions on the basis of CEA trend rather than the results of single measurements, looking at the potential to avoid both missed cases of recurrence and false alarms.
Methods
This was a secondary observational analysis of data from the FACS trial, a 2 × 2 pragmatic randomized factorial controlled trial comparing minimum follow-up after surgery for colorectal cancer for 5 years, with blood tests every 3-6 months for CEA and CT every 6-12 months 6 . The testing schedule is detailed in Tables S1 and S2 (supporting information). Patients who had undergone curative surgery for primary colorectal cancer and, after extensive testing (histology, imaging and CEA measurement, showing a level no higher than 10 μg/l), were confirmed to have no residual disease, were recruited between 2003 and 2009 from 39 National Health Service (NHS) hospitals across England. The CEA analysis was undertaken using a Siemens Centaur XP ® analyser (Erlangen, Germany) at a single laboratory, with a standard quality control regimen to ensure longitudinal stability. If the blood CEA level was 7 μg/l or more above the patient's baseline level (which was measured on entry to the trial) after repeat measurement, the general practitioner was asked to refer the patient urgently to the local hospital for further investigation. The reference standard in the study was clinical diagnosis of colorectal cancer recurrence as determined by the multidisciplinary team at each hospital centre. As this was a pragmatic clinical trial in an NHS setting, all available evidence (which varied between hospitals and individual patients) was used to determine a diagnosis of recurrence, including imaging and biopsy results. All participating centres were bowel cancer specialist centres with diagnostic experience and expertise. Investigation for suspected recurrence could be triggered as a result of abnormal results on per-protocol colonoscopy or CT, a CEA level more than 7 μg/l above the patient's personal baseline, or suspicious symptoms.
The accuracy of trend in an individual's serial CEA measurements was compared with interpreting single CEA measurements. Linear regression models were fitted to each individual's serial CEA measurements, and the β coefficient was extracted from each model to quantify trend. In previously reported single-measurement evaluations, the CEA measurement at the time of diagnosis of recurrence was often selected for analysis 15 , but this may overestimate the accuracy as in clinical practice all measurements are interpreted prospectively. The authors therefore looked across all measurements for each individual and identified, based on all possible thresholds (a threshold of 5 μg/l is referred to in the results as this is most commonly reported 15 ), whether their measurements had risen above the threshold at any time point. Time-dependent receiver operating characteristic (ROC) curve analysis was used to demonstrate the trade-off between sensitivity and specificity when clinical decisions are based on different degrees of trend. The area under the curve (AUC) is also reported. All analyses were undertaken using the statistical package R (http://www.R-project.org/); the time-dependent ROC curve analysis was carried out using the R package timeROC 16 .
Results Table 1 shows the clinical characteristics of patients included in the analysis. The median number of CEA measurements available for each participant was 13 (i.q.r. [10] [11] [12] [13] [14] , with a median of 6 (3-9) measurements in patients who developed recurrence and 14 (13, 14) for those who did not. This included all individuals who had at least two CEA measurements available, but this means that individuals with a recurrence detected in the first 3 months were excluded. The analysis was based on 582 of the 602 patients allocated to the two arms of the study who received CEA testing (Fig. S1 , supporting information). Some 96 of the 104 patients with recurrence had undergone at least two CEA tests; of these, six had a falling level, six had an initial fall before a rise, 13 had stable levels, and 23 had a rising CEA level that did not exceed the 5-μg/l threshold. Even among the 52 patients whose CEA did rise above 5 μg/l, it took a median of 15⋅9 (i.q.r. 6⋅8-29⋅9) months for the level to rise above the threshold. Of the 478 patients without recurrence, 15 (3⋅1 per cent) had two or more raised CEA measurements above 5 μg/l within the study interval. These false alarms occurred in 12 per cent of current smokers (at time of the study) and 2⋅7 per cent of non-smokers (odds ratio 4⋅43, 95 per cent c.i. 1⋅34 to 14⋅7; P = 0⋅015). Current smokers should therefore be informed of the false alarm risk and be followed up with a different modality, such as CT of the chest, abdomen and pelvis. Fig. 1 compares the trend in CEA levels in patients with and without recurrence. CEA levels tended to be very stable in patients free from recurrence, but those in patients Values in parentheses are percentages. with disease recurrence had a variable trend with a 100-fold standard deviation. Fig. 2 shows the time-dependent ROC curves at year 1 for making the decision to investigate on the basis of trend in serial CEA measurements compared with single measurements. Across all years of follow-up, the AUC for the trend in CEA measurements remained over 0⋅800 ( Table 2 ). The time-dependent AUC estimates for the trend analysis were consistently higher than those for single measurements, although in some instances the 95 per cent confidence intervals overlapped. This appeared to be constrained to a maximum sensitivity of 70 per cent without losing substantial test specificity. Making decisions based on trends in CEA levels would not allow CEA alone to be used as a triage test because, even at the point of optimal trade-off between sensitivity and specificity, three in ten recurrences would be missed. Additional tests to maintain sensitivity would need to be carried out in accordance with local protocol. Details of additional testing and associated timings within the FACS trial are described in Tables S1 and S2 (supporting information). The time-dependent ROC analysis allowed exploration of optimal thresholds for interpreting trend (change per year). These were: year 1, 1⋅7 μg/l; year 2, 1⋅4 μg/l; year 3, 0⋅8 μg/l; year 4, 0⋅5 μg/l; year 5, 0⋅3 μg/l.
Discussion
Although there is still debate about the benefits of surveillance 17 , most clinicians continue to monitor CEA in addition to performing CT at intervals with the aim of detecting recurrence before symptoms develop. The present results suggest that the diagnostic accuracy of CEA trends is better than the result of a single measurement, but a substantial number of recurrences would still be missed if trends in CEA were used as a single surveillance method.
In the absence of alternative markers, the authors can make some suggestions for an improved CEA monitoring schedule based on the FACS data. In the FACS protocol, 3-monthly measurements in year 2 of follow-up and 6-monthly measurements for the remaining time were sufficient to monitor trends. As almost half of the recurrences were identified during the first year of follow-up, however, a CEA monitoring schedule that consists of monthly measurements in the first 3 months and every 2 months for the remainder of the first year is recommended. This would ensure that enough measurements were taken to observe a trend during early follow-up (2 months onwards). In the first couple of months, single test measurements would still have to be interpreted. Possible thresholds for interpreting trend (change per year) require further validation before implementation in clinical practice. To facilitate interpretation, laboratories could report trend over time as well as the absolute CEA level.
The cost-effectiveness and feasibility of such an intensive testing schedule needs to be evaluated fully. The mean direct NHS cost of CEA testing in the FACS trial was estimated at £7⋅50 per test (€8⋅40; exchange rate 13 January 2018), so the cost of the additional four tests in year 1 would be approximately £30 (€34), not taking account of subsequent price inflation 18 . A recent study 19 in the Netherlands, the CEAwatch trial, investigated an intensive follow-up protocol that included more frequent CEA measurements (bimonthly), but fewer outpatient visits, which detected more curable recurrences than standard practice. An economic evaluation of the trial, which included direct medical costs, productivity losses and travel expenses, was conducted and the incremental cost-effectiveness ratio per curable recurrence was calculated. It was found that an additional US $60 700 (€51 465 in original article) would be needed to detect one additional patient with curable recurrent disease. Although the authors considered this to be acceptably low 19 , until the quality-of-life and survival benefits of detecting recurrence before symptoms develop are known, definitive conclusions are not possible 18 .
The main strengths of the FACS trial are that the analysis was undertaken on well staged patients with robust outcome data. The CEA testing was managed centrally with good compliance, and all analyses were done in a single laboratory. The main limitation is that a reference standard was not available at all time points. The precise time at which a recurrence would have been detectable by a trend-based analysis is not known. However, the length of follow-up and within-trial surveillance means that missed recurrences were unlikely. There may have existed a work-up bias as patients with a CEA level of 7 μg/l or more above their personal baseline were referred for further investigation; however, this selected threshold is higher than the usual reported threshold (5 μg/l) 15 . Owing to the small number of recurrences, it is not possible to use the FACS data to develop a definitive model and cut-off values that clinicians could use to interpret trends in CEA levels. Ideally, this would explore other factors that may bring granularity to the interpretation of individual trends, such as smoking status, tumour site and stage.
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